At Life Academy of Shimen Mountain in 2020
(2020 年攝於石門山圓桌教育中心)

Yi-Wen Liu 劉 怡 文

Address (連絡地址)：

Room A25-304, No. 300, Syuefu Road, Chiayi 600, Taiwan
TEL: 886-5-2717809
FAX: 886-5-2717831
Email: ywlss@mail.ncyu.edu.tw
(600 嘉義市學府路 300 號生命科學館 A25-304 室)

Present Position (現職)

[2012/08-present] Professor at Department of Microbiology, Immunology and Biopharmaceuticals, National Chiayi University, Chiayi, Taiwan.
(國立嘉義大學 微生物免疫與生物藥學系 教授)

[2024/02-present] Vice Dean and Team Leader of Division of Student Assistance of Student Affair in National Chiayi University
(國立嘉義大學 副學生事務長兼生活輔導組組長)

[2022/02-present] Vice Dean of Student Affair in National Chiayi University
(國立嘉義大學 副學生事務長)

[2023/08-present] Consultation experts in Medical Ethics Review Board and Institutional Review Board of St. Martin de Porres Hospital
(天主教聖馬爾定醫院 醫療倫理暨人體試驗委員會諮詢專家)

[2023/06-present] Committee member in Medical Ethics Review Board of Ditmanson Medical Foundation Chia-Yi Christian Hospital

(戴德森醫療財團法人嘉義基督教醫院 醫療倫理審查委員會委員)

[2012/03-present] Committee member in Institutional Review Board of Ditmanson Medical Foundation Chia-Yi Christian Hospital
(戴德森醫療財團法人嘉義基督教醫院 研究倫理審查委員會委員)

[2011/09-present] Committee member in Human bank Ethic Committee of Ditmanson Medical Foundation Chia-Yi Christian Hospital
(戴德森醫療財團法人嘉義基督教醫院 人體生物資料庫倫理委員會委員)

Education (學歷)：

[1997/06] Ph.D. from Department of Basic Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
(國立成功大學醫學院 基礎醫學博士)

[1993/06] M.S. from Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
(國立成功大學醫學院 藥理學碩士)

[1991/06] B.S. from Department of Pharmacy, Kaohsing Medical School, Kaohsing, Taiwan.
(高雄醫學院 (現為高雄醫學大學) 藥學系學士 (R31))

Professional License (專業證照)：

Pharmacist in Taiwan
(台灣藥師證書)

Service and past Career Positions (服務與工作經歷)：

[2024/01-present] Deacon of Presbyterian Church in Taiwan - Chiayi Ximen Church
(台灣基督教長老教會 嘉義西門教會 執事)

[2022/01-2023/12] Chairman of Women's Fellowship of Presbyterian Church in Taiwan - Chiayi Ximen Church
(台灣基督教長老教會 嘉義西門教會 婦女團契 會長)

[2014/10-2015/09] Chairman of Parents Committee of Ta-Tung Elementary School in Chiayi City
(嘉義市大同國小 家長委員會 會長)

[2013/08-present] Volunteer Service in Life Academy Foundation
(圓桌教育基金會 志工)

[2010/08-2012/07] Associate Professor at Department of Microbiology, Immunology and Biopharmaceuticals, National Chiayi University. Chiayi, Taiwan.
(國立嘉義大學 微生物免疫與生物藥學系 副教授)

[2010/08-2011/07] Serve in the special assistant of Life Sciences College
(兼任生命科學院 特別助理)

[2007/08-2010/07] Associate Professor at Graduate Institute of Biomedical and Biopharmaceutical Sciences, National Chiayi University. Chiayi, Taiwan.
(國立嘉義大學 生物醫藥科學研究所 副教授)

[2002/08-2007/07] Assistant Professor at Graduate Institute of Biopharmaceutics, National Chiayi University. Chiayi, Taiwan.
(國立嘉義大學 生物藥學研究所 助理教授)

[2000/08-2002/07] Assistant Professor at Department of Pharmacy, Chia Nan University of Pharmacy and Science. Tainan, Taiwan.
(嘉南藥理科技大學 藥學系 助理教授)

[1998/08-2000/03] Research Specialist at Biotechnology Development Program, Research & Development Division, China Chemical & Pharmaceutical Co., LTD. Taipei, Taiwan.
(中國化學製藥股份有限公司 研發處生物科技專案室 研發專員)

[1997/08-1998/07] Postdoctor at Department of Pharmacology, National Taiwan University. Taipei, Taiwan.
(國立台灣大學醫學院 藥理學科 博士後研究員)

Honor/Awards (榮譽獎項)：

[2023] The Reward for Performance Excellence in Higher Education Sprout Project of National Chiayi University of 2023
(112 年度國立嘉義大學高等教育深耕計畫績效卓越獎勵)

[2022] The Reward for Excellent Performance in Higher Education Sprout Project of National Chiayi University of 2022
(111 年度國立嘉義大學高等教育深耕計畫績效優秀獎勵)

[2021] The Reward for Excellent Researcher in University from MOST of 2021
(110 學年度科技部補助大專校院獎勵特殊優秀人才)

[2020] Distinguished Professor at National Chiayi University in 2020-2021
(109-110 年國立嘉義大學特聘教授)

[2020] The Teaching Distinguished Award of 2020, National Chiayi University
(國立嘉義大學 109 學年度教學特優獎)

[2020] The Reward for Excellent Researcher in University from MOST of 2020
(109 學年度科技部補助大專校院獎勵特殊優秀人才)

[2018] The Reward for Excellent Researcher in University from MOST of 2018
(107 學年度科技部補助大專校院獎勵特殊優秀人才)

[2017] The Reward for Excellent Researcher in University from MOST of 2017
(106 學年度科技部補助大專校院獎勵特殊優秀人才)

[2015] The Reward for Excellent Researcher in University from MOST of 2015
(104 學年度科技部補助大專校院獎勵特殊優秀人才)

[2014] The Reward for Excellent Researcher in University from MOST of 2014
(103 學年度科技部補助大專校院獎勵特殊優秀人才)

[2013] The Reward for Excellent Researcher in University from NSC of 2013
(102 學年度國科會補助大專校院獎勵特殊優秀人才)

[2012] The Reward for Excellent Researcher in University from NSC of 2012
(101 學年度國科會補助大專校院獎勵特殊優秀人才)

[2011] The Teacher Service Excellent Award of 2011, National Chiayi University
(國立嘉義大學 99 學年度教師服務優良獎)

[2007] The Teaching Recognition Award of 2007, National Chiayi University
(國立嘉義大學 95 學年度教學肯定獎)

[1997] Oral Presentation/Excellent Award of Dr. Chien-Tien Hsu memorial. The 5th International Symposium on Recent Advances in Cellular and Molecular Biology, Taiwan.
(第 5 屆細胞與分子生物新知研討會 徐千田博士紀念口頭報告優秀論文獎)

[1995] Oral Presentation/Excellent Award from Dr. Chien-Tien Hsu memorial. The 3th International Symposium on Recent Advances in Cellular and Molecular Biology, Taiwan.
(第 3 屆細胞與分子生物新知研討會 徐千田博士紀念口頭報告優秀論文獎)

[1993] Poster Presentation Distinguished Achievement Award. The 5th Society of Chinese Bioscientists in America International Symposium, USA.
(第 5 屆美洲華人生物科學國際研討會 壁報展示優秀論文獎)

Laboratory staffs (實驗室成員)：

Research assistant (研究助理)

- 魏惠敏 (嘉義大學微生物免疫與生物藥學系/中山大學生物醫學所畢業)

Ph.D. students (博士班研究生)

- In school (在學)：
- Graduated (已畢業)：林美儀醫師(中國醫藥大學中醫學系博班)、王守琮(嘉義大學食品科學系博班)、王守玠醫師(嘉義大學食品科學系博班)。

Master students (碩士班研究生) (*表示該生繼續攻讀博士班)

- In school (在學)：吳佩璇
- Graduated (已畢業)：陳俊嘉、李曜騰醫師、吳妍穎、楊晉瑚、黃鈺琄*(成大博班畢)、陳淑幸、許資依、張偉民*(國防博班畢)、鍾欣怡、吳欣蓉*(成大博班畢)、蔡坤維醫師、陳克宇、李宜蓁、林怡玟*(清華博班畢)、廖禹涵*(成大博班畢)、楊筑驛、張益昇、陳信旭、林永倫、鄭長晉、劉筱媛、林淑貞、陳泱亦、劉宏德、陳佩青、Mohammad Megbahul Haque (from Bangladesh)、趙珮雯、王守琮*(嘉大博班畢)、陳詩穎、鄧羽喬、王琦泓、戴元昌醫師*(中興博班)、楊子瑩、

李姵諭、李嘉雯。

Undergraduate students (大學生) (🕮:取得科技部大專生計畫、*表繼續攻讀碩士班)

- In school (在學)：張予綸、黃緯秦、蔡元豪、鍾育軒、賴俞丞、李婉甄。
- Graduated (已畢業)：🕮蔡政良*、潘瑩霞、蔡易達*、高智國*、賴怡君*、陳俊傑*、張益昇*、魏惠敏*、鄭文慶、莊舒涵*、鄞秋涵*、陳欣俞*、甯欣慈*、賴怡蒨*、🕮陳佩青*、林建瑜*、🕮施盈均*(台大博班畢)、林威漢*、張朝欽*、趙珮雯*、詹郁恬*、曾雅嫻*、陳玫芳*、粘介銘*、林子雯*、🕮王翔昱*、程卉華*、黃永齡*、🕮賴純資、🕮張庭嘉*、丁佩旻、余旻樺*、🕮顏宇君、賴宸緯*(陽明交大博班)、李念綺*、李欣柔*(陽明交大博班)、李嘉雯*、蕭英裕、陳可欣、余詠樂、謝芝羽、洪晨泰*、🕮劉佩俞*、周思佑*、🕮陳玟霖、朱珮綺、🕮蔡蕎伃*、余陳昊鴻*、🕮劉冠萬*、🕮唐煒祐*、吳佩璇*、許庭羽。

畢 業 生 就 業 情 形		
姓 名	**任 職 單 位**	**職 稱**
張偉民	台北醫學大學 口腔衛生學系	助理教授
林威漢	漢康生技股份有限公司	研究員
陳欣俞	圓祥生技公司	副研究員
廖禹涵	成功大學醫學院藥理所	博士後研究員
李姵諭	嘉義基督教醫院	醫檢師
陳淑幸	嘉義基督教醫院	助理研究員
李宜蓁	林口長庚醫院	助理研究員
趙珮雯	嘉義基督教醫院	助理研究員
施盈均	國家衛生研究院 免疫醫學研究中心	博士後研究員
林永倫	中國醫藥大學	助理研究員
王琦泓	中國醫藥大學	助理研究員
林建瑜	育世博股份有限公司	研究員
陳佩青	中化合成生技股份有限公司	品管課工程師
劉宏德	嘉義長庚醫院	助理研究員
莊舒涵	財團法人藥物救濟基金會 藥物安全組	組員
鄞秋涵	群創光電 製程整合工程	工程師
鄭文慶	嘉義市消防局	消防隊員
魏惠敏	嘉義大學微藥系	助理研究員
曾雅嫻	嬌生公司	品質工程師
鄭長晉	嘉義大學總務處	職員
甯欣慈	全福生物科技股份有限公司	專案經理
賴怡蒨	啓弘生物科技股份有限公司	助理研究員
楊子瑩	嘉義長庚醫院	研究助理
張庭嘉	南光化學製藥股份有限公司	助理研究員
陳詩穎	南光化學製藥股份有限公司	助理研究員
鄧羽喬	農業科技研究院 生物安全部門	組員
陳泱亦	台大基因體中心	助理研究員
陳信旭	群耕農業生技有限公司 農業資材部	副理

余旻樺	中國醫藥大學	助理研究員
黃鈺琄	中央研究院	博士後研究員
林怡玟	台灣圓點奈米技術股份有限公司 試劑研發處	主任
粘介銘	高醫學士後醫學系	醫學生
林子雯	聯亞生技 臨床試驗處	管理專員
王翔昱	中國醫藥大學 臨床試驗中心	臨床試驗助理
賴純資	神盾股份有限公司 品管部門	組員
王守琮	嘉義大學獸醫系	醫學生
程卉華	百瑞精鼎國際股份有限公司	臨床資料分析師
高智國	綠茵生技股份有限公司	研發工程師
鍾欣怡	喬本生醫股份有限公司 研發部	主管特助
張朝欽	家畜衛生試驗所	研究助理
劉筱媛	康儀科技股份有限公司	業務專員
蕭英裕	藥華醫藥股份有限公司 生產部	組員
李嘉雯	壽元化學股份有限公司 研發部	組員
李念綺	松瑞製藥股份有限公司 品保部	組員
若有更新，請私訊(或 Line)老師告知，謝謝。		

Teaching Course (教學科目)：

Pharmacology (藥理學)、Medicinal Chemistry (藥物化學)、Chemotherapy (化學治療法)、Chemistry (普通化學)、Cell Biology (細胞生物學)、Microbiology Experiment (微生物學實驗) 、Biomedicine (生物醫藥學)

Research Expertise (研究專長)：

1. Development of anti-bladder cancer drugs and diagnostic biomarker of bladder cancer (抗膀胱癌藥物開發與診斷膀胱癌之生物指標研究)

   Bladder cancer is highly recurrent following specific transurethral resection and intravesical chemotherapy, which has prompted continuing efforts to develop novel therapeutic agents and early-stage diagnostic tools. Our laboratory is the earliest research team in Taiwan to establish a mouse orthotropic bladder tumor model and already has five international publications in therapeutic chemical studies in this model. We also focus on the gene expression change in bladder tumorigenesis. We have five international publications in this field. Because the number of patients with bladder cancer is higher in south Taiwan than in other area, we have cooperated with Ditmanson Medical Foundation Chia-Yi Christian Hospital for bladder cancer study. Our team

wants to find new methods for diagnostic, chemotherapy, immunotherapy, and chemoprevention of bladder cancer.

(膀胱癌是一種復發率極高的癌症，即使對於未肌肉侵犯型膀胱癌使用經尿道腫瘤切除術與經尿道化療藥物灌注療法後，復發率仍然高。因此我們一方面希望能尋找新的化學治療藥物，另一方面則是希望能夠找到簡便之早期偵測膀胱癌方法，以利病患早期發現予以治療。我們是台灣最早建立起小鼠膀胱原位癌植入技術與治療模式的實驗室，利用這技術在新藥開發上已發表5篇相關國際文獻。另外，我們也研究在膀胱癌形成中的基因表現變化，這方面相關研究已發表5篇國際文獻。由於台灣南部罹患膀胱癌的患者多過其他地區，因此我們長期與戴德森嘉義基督教醫院合作，我們的研究團隊一直朝開發新的無侵犯性膀胱癌診斷方法、新的藥物治療、免疫療法、以及化學預防方法而努力。)

2. Ketamine-induced bladder disorder (K 他命致膀胱異常之機轉研究)

Ketamine is used clinically for anesthesia but is also abused as a recreational drug. It is known that ketamine-induced bladder interstitial cystitis is a common syndrome in ketamine-abusing individuals. As the mechanisms underlying ketamine-induced cystitis have yet to be revealed, we also investigate in this field. We hope to find a better method for protecting ketamine-induced bladder interstitial cystitis. We have three international publications in this field.

(K他命是一種臨床麻醉劑，但同時也是一種微具成癮性之娛樂性濫用藥品。目前已知長期K他命濫用者容易引發膀胱間質性發炎，而目前對於這樣的病徵理解程度尚不足，因此，我們也在這區塊有研究，希望藉由了解致病機轉而找到更好的方法，用來治療K他命濫用所引發之膀胱間質性發炎現象。我們在這方面研究已發表3篇國際文獻。)

3. Anti-inflammation study (抗發炎相關研究)

Inflammation is one important factor in many diseases, therefore, anti-inflammation research is a long-lasting field for biomedicine study. In our study, the cellular response of urothelia infected by *C. albicans* was investigated. We found that *C. albicans* caused the bladder epithelial cells morphology change, cell damage, cell de-attachment, and inflammatory response, including cyclooxygenase-2 gene and protein expression, PGE2 accumulation, and interleukin-8 gene expression. The more we understand the inflammatory mechanism, the more we can do for prevention and cure. Now we want to find useful anti-inflammatory medicines from natural products for clinical patients. (發炎是許多疾病的重要因素之一，因此，抗發炎研究在生物醫學領域是一項歷久不衰的研究方向。我們實驗室曾針對白色念珠菌感染泌尿道上皮細胞的機制做研究，發現受感染的細胞不但形狀改變、細胞面臨脫落與死亡威脅，也引發發炎反應，包括環氧酵素 2 基因誘發、PGE_2 產量累積、介白素 8 基因活化等。當我們了解細胞發炎機制越詳細，我們越能設計出更好的方法來做預防與治療。目前我們希望結合中草藥研發實用之抗發炎藥物，提供臨床上病患使用。)

Journal Editorial Board Member (期刊編輯委員)：

1. Journal of Microbiology and Modern Techniques (2016-present)
2. Molecular Medicine Reports (2019-present)
3. Oncology Letters (2019-present)
4. Journal of Clinical & Translational Research (2024-present)
5. Processes (A special issue editor in 2021-2022)
6. Nutrients (A special issue editor in 2023-2024)

Journal Reviewer (期刊審查委員)：

1. Acta Pharmacologica Sinica
2. American Journal of Cancer Research
3. Archives of Medical Science
4. African Journal of Agriculture Research
5. Biochemical Pharmacology
6. Bioengineered
7. Biomedicine & Pharmacotherapy
8. BMC Complementary and Alternative Medicine
9. British Journal of Pharmacology
10. Cancers
11. Cells
12. Chemotherapy
13. Chinese Journal of Physiology
14. Clinical Epigenetics
15. Drug and Chemical Toxicology
16. Ecotoxicology and Environmental Safety
17. Evidence-Based Complementary and Alternative Medicine
18. Experimental and Molecular Pathology
19. Experimental and Therapeutic Medicine

20. Exposure and Health

21. Fitoterapia

22. Food and Chemical Toxicology

23. Gene Reports

24. Heliyon

25. Immunology

26. Indian Journal of Biochemistry & Biophysics

27. Inflammation

28. International Immunopharmacology

29. International Journal of Biological Macromolecules

30. International Journal of Medical Sciences

31. International Journal of Molecular Medicine

32. International Journal of Molecular Sciences

33. International Journal of Urology

34. Journal of Agricultural and Food Chemistry

35. Journal of Cellular and Molecular Medicine

36. Journal of Chinese Integrative Medicine

37. Journal of Clinical Laboratory Analysis

38. Journal of Ethnopharmacology

39. Journal of Nature Products

40. Letters in Drug Design & Discovery

41. Life Sciences

42. Molecular Biology Reports

43. Molecular and Clinical Oncology

44. Molecular Medicine Reports

45. Molecular Nutrition and Food Research

46. Oncology Letters

47. Oncology Reports

48. Pharmaceutical Biology

49. Pharmacological Research

50. Pharmacology & Therapeutics

51. Pharmacology

52. PLOS ONE

53. Scientific Reports

54. The American Journal of Physiology - Renal Physiology

55. The Chinese Journal of Physiology

56. The Kaohsiung Journal of Medical Sciences

57. The Malaysian Journal of Pathology

58. The Journal of Pharmacology and Experimental Therapeutics (JPET)

59. Tissue and Cell

Grants from National Science and Technology Council (國科會研究計畫)：

A. Investigator (主持人)

	Title (Year) 計畫名稱 (執行期間)	Code 計畫編號	Budget 經費 (x 10^3 元)	Status 狀態
1	Combination of marketed drugs for a new opportunity of bladder cancer therapy (2023/8/1~2024/7/31) 使用已上市藥物的組合，為膀胱癌治療打開新契機 (2023/8/1~2024/7/31)	NSTC 112-2320-B-415-002	1,250	執行畢

2	Epigenetic and transcriptional regulation of glutathione-related genes in diagnosis and treatment of urothelial carcinoma (2019/8/1~2022/7/31) 研究與穀胱甘肽相關基因之表觀基因與轉錄調節機制，並應用於泌尿上皮癌之診斷與治療 (2019/8/1~2022/7/31)	MOST 108-2320-B-415-006-MY3	4,592 (三年計畫)	執行畢
3	Application of gene expression regulation and epigenetic study of glutathione S-transferase M family in the diagnosis and chemotherapy of urothelial carcinoma (2018/8/1~2019/7/31) 將谷胱甘肽轉移酶M家族之基因表現調節與表觀基因研究應用於泌尿上皮癌之診斷與化療輔助 (2018/8/1~2019/7/31)	MOST 107-2320-B-415-001	850	執行畢
4	The role of DNA CpG island methylation in bladder carcinogenesis and transitional cell carcinoma progression. (2015/8/1~2018/7/31) 基因 CpG 島甲基化在膀胱癌形成與移行性上皮癌細胞惡化中所扮演之角色 (2015/8/1~2018/7/31)	MOST 104-2320-B-415-001-MY3	3,420 (三年計畫)	執行畢
5	Sequential change of histology and mechanism study of gene expression regulation in bladder urothelium carcinogenesis. (2012/8/1~2015/7/31) 膀胱上皮細胞癌化過程中之連續組織學變化與基因表現調節機轉探討 (2012/8/1~2015/7/31)	NSC101-2320-B-415-002-MY3	3,900 (三年計畫)	執行畢
6	Establishment of mice bladder tumor model and study of metastatic mechanism of bladder cancer cells (2009/8/1~2012/7/31) 建立小鼠膀胱癌模式與探討膀胱癌細胞之轉移機制 (2009/8/1~2012/7/31)	NSC98-2320-B-415-002-MY3	2,750 (三年計畫)	執行畢

7	Cytotoxicity, anti-metastatic study and in vivo anti-tumor effect of Combretastatin A-4 in human bladder cancer (2008/8/1~2009/7/31) 探討 Combretastatin A-4 對人類膀胱癌的毒殺與抗轉移特性與活體腫瘤抑制效果 (2008/8/1 ~ 2009/7/31)	NSC97-2320-B-415-002-	872	執行畢
8	Mechanism study of LPS and PGN-induced C/EBPdelta gene activation in mouse macrophages (2006/8/1~2007/7/31) 探討 LPS 與 PGN 活化老鼠巨噬細胞 C/EBPdelta 基因之細胞內機轉 (2006/8/1~2007/7/31)	NSC95-2320-B-415-004-	802	執行畢
9	Analysis of functional region of C/EBPdelta gene promoter induced by lipopolysaccharide in mouse macrophages (2004/8/1~2005/7/31) 脂多糖活化老鼠 C/EBPdelta 基因啟動子之功能性區段分析 (2004/8/1 ~2005/7/31)	NSC93-2320-B-415-002-	630	執行畢
10	Study of lipopolysaccharide-induced interleukin-10 gene expression in mouse monocyte RAW264.7 (2002/8/1~2003/7/31) 脂多糖誘導老鼠單核球細胞 RAW264.7 間質素十基因表現之探討 (2002/8/1 ~2003/7/31)	NSC91-2320-B-415-003-	1,000	執行畢
11	Regulation of mouse interleukin-10 gene expression by lipopolysaccharide (2001/8/1~2002/7/31) 脂多糖對老鼠間質素十基因表現之調節 (2001/8/1~2002/7/31)	NSC90-2320-B-415-017-	831.6	執行畢
12	Signal transduction of LPS-induced gene expression of mouse interleukin-10 (2000/11/1~2001/7/31)	NSC89-2320-B-415-017-	519.4	執行畢

	脂多糖刺激老鼠間質素十基因表現之細胞內訊息傳遞路徑研究 (2000/11/1~2001/7/31)			

B. Co-Investigator (共同主持人)

	Title (Year) 計畫名稱 (執行期間)	Code 計畫編號	Budget 經費 (x 10^3 元)	Status 狀態
1	探討一種新穎藥物於活體內治療人類多重抗藥性及未分化甲狀腺癌之效果與其機制，並應用於與臨床用藥協同治療 (2020/8/1~2021/10/31)	MOST109-2314-B-037-145	1,180	執行畢
2	Evaluation of anti-tumor effects and the mechanisms of flavopereirine on human thyroid cancers. (2015/8/1~2016/7/31) Flavopereirine抑制人類甲狀腺癌之效果與機制探討 (2015/8/1~2016/7/31)	MOST 104-2314-B-705-003	800	執行畢
3	Ras induced tumorigenesis is regulated by autophagic degradation of cell cycle related proteins and development of specific drugs for Ras-> autophagy-> tumorigenesis by connectivity map. (2012/8/1~2015/7/31) 自體吞噬藉分解細胞週期蛋白調控 Ras 相關之腫瘤發生並利用 connectivity map 開發 Ras->細胞自噬->腫瘤生成之藥物 (2012/8/1~2015/7/31)	NSC101-2320-B-006-025-MY3	4,800 (三年計畫)	執行畢
4	The effect of anti-tumor growth and inducing cell death mechanism of reversine on thyroid cancer cell lines (2010/8/1~2012/7/31) 評估 reversine 對甲狀腺癌細胞株的抑癌生長效果與誘發細胞死亡機制之探討 (2010/8/1~2012/7/31)	NSC99-2314-B-705-002-MY2	1,960 (二年計畫)	執行畢
5	Effect of peanut resveratrol and its derivatives in prevention of aging-related diseases and	NSC95-2321-B-	4,239 (三年計畫)	執行

	extension of lifespan (2006/8/1 ~ 2009/7/31) 花生白藜蘆醇及其衍生物預防老化相關疾病與延長壽命之探討 (2006/8/1 ~ 2009/7/31)	415-001-		畢
6	Evaluation on immuno-enhance of anti-SARS Chinese medicinal decoctions (2003/11/1~2004/10/31) 防疫方劑之免疫增強評估 (2003/11/1~2004/10/31)	SARS 專案研究計畫 92IISCHM08	993.6	執行畢

C. Advisor of undergraduate research program (指導國科會大專生專題研究計畫)

	Title (Year) 計畫名稱 (執行期間)	Code 計畫編號	Budget 經費 (x 10^4 元)	Student 學生
1	探討小蘗鹼 (Berberine)與其衍生物(10e、13e)誘導膀胱癌細胞 BFTC 905 之死亡機制 (2023/7/1~2024/2/28)	NSTC 112-2813- C-415-047- B	5.8	唐煒祐
2	探討新型 Vorinostat 衍 生物對膀胱癌的抗癌活性與機轉 (2023/7/1~2024/2/28)	NSTC 112-2813- C-415-048- B	4.8	劉冠萬
3	探討小蘗紅鹼衍生物誘導膀胱癌細胞 Glutathione *S*-transferase Mu 2表現之效果與細胞生理影響 (2022/7/1~2023/2/28)	NSTC 111-2813-C-415-059-B	5.8	陳玟霖
4	探討佩你安及其衍生物與Vorinostat或Thalidomide的組合在膀胱癌細胞的抗癌活性 (2022/7/1~2023/2/28)	NSTC 111-2813-C-415-060-B	5.8	蔡蕎伃
5	探討植化素Berberrubine誘導GSTM2表現之效果及機轉 (2021/7/1~2022/2/28)	110-2813-C-415-066-B	4.8	劉佩俞同學
6	尋找提升人類GSTM4基因轉錄活性之轉錄因子與小分子化合物 (2018/7/1~2019/2/28)	107-2813-C-415-102-B	4.8	顏宇君同學
7	Cloning and activity analysis of human	106-2813-C-	4.8	張庭嘉

	GSTM5 gene promoter using luciferase reporter plasmid (2017/7/1 ~ 2018/2/28)	415- 048-B		同學
8	Vorinostat 於膀胱癌中抗癌機制探討與小鼠膀胱癌之經尿道給藥治療效果 (2017/7/1 ~ 2018/2/28)	106-2813-C-415- 049-B	4.8	賴純資同學
9	Trichostatin A引發人類膀胱癌細胞死亡機制探討與小鼠原位膀胱癌之治療效果評估 (2015/7/1 ~ 2016/2/28)	104-2815-C-415-002-B	4.8	王翔昱同學
10	人類泌尿道上皮細胞與光滑念珠菌共同培養後之 cyclooxugenase-2 基因表現分析並投以抗發炎藥物觀察是否降低發炎現象（2013/7/1 ~ 2014/2/28)	102-2815-C-415-031-B	4.7	施盈均同學
11	人類泌尿道上皮細胞與念珠菌共同培養後發炎相關基因表現分析 (2012/7/1 ~ 2013/2/28)	101-2815-C-415-018-B	4.7	陳佩青同學
12	胜肽多糖活化老鼠 C/EBPdelta 基因表現之分析 (2005/7/1 ~ 2006/2/28)	94-2815-C-415-007-B	4.7	蔡政良同學

Grants from Industry (產學研究計畫)：

A. Investigator (主持人)

	Title (Year) 計畫名稱 (執行期間)	Code 計畫編號	Budget 經費 (x 10^3 元)	Status 狀態
1	Study the anti-cancer mechanism of vorinostat derivatives 6e, 6e-HCl, and the anti-bladder tumor activity in a mouse tumor model (2024/7/1~2025/6/30) 探討 vorinostat 衍生物 6e、6e-HCl 的抗癌機轉與其在小鼠腫瘤模式的抗癌活性 (2024/7/1~2025/6/30)		380	執行中
2	Screening the anti-cancer activity of cyproheptadine, its derivatives and combination with vorinostat or thalidomide in	Shen-1	1,500 (二年計畫)	執行畢

	bladder cancer cell lines and in mouse tumor models (2022/1/1~2023/12/31) 以膀胱癌細胞和小鼠腫瘤模式篩選並分析佩你安，其衍生物以及與vorinostat或thalidomide組合的抗癌活性 (2022/1/1~2023/12/31)			

Research advising for high school students (高中生研究指導)：

	Name (Year) 姓名 (年度)	High school 高中	Status 狀態
1	蕭秉修、蘇愛甯、侯姵君 (2024)	嘉華高中	執行中
2	周昕俞(2023)	協同高中	執行中
3	黃亮昕(2022)	嘉義高中科學班	執行畢
4	黃亮昕、洪楷捷、陳冠邑 (2021)	嘉義高中科學班	執行畢
5	吳惠雯(2021)	嘉義高中科學班	執行畢
6	吳惠雯、劉宸安、劉宸宇 (2020)	嘉義高中科學班	執行畢

🕮 Patent (專利)

1. 發明人：林美儀、**劉怡文**、李明陽、陳瑞傳。發明名稱：皮膚敷藥的中藥成分、皮膚敷藥及其製造方法。中華民國專利證書 發明第 I788648 號，期間：2023/1/1-2040/3/29

🕮 Professional Publication (專業著作)

1. 藥理學快讀入門。2021，譯者：**劉怡文**。合記圖書出版社發行，ISBN 978-986-368-

423-7。翻譯自 Medical Pharmacology at a Glance (9th Edition，2020，Wiley Blackwell) (ISBN 978-1-119-54801-0)，原著：Michael J. Neal。

🕮 Academic Publication (學術著作)

Journal publications (first author, corresponding author*, 2022 JCR)

期刊論文發表 (以藍色字表示 YWL 為該篇之第一作者或通訊作者*)

[2008 年至今，First author, corresponding author*]

1. I.C. Lin, J.Y. Wu, C.Y. Fang, S.C. Wang, **Yi-Wen Liu***, Shang-Tse Ho*. Absorption and Metabolism of Urolithin A and Ellagic acid in Mice and Their Cytotoxicity in Human Colorectal Cancer Cells. **Evidence-based Complementary and Alternative Medicine 2023/09**, 2023: 8264716. (SCIE in 2021, IF 2.65, INTEGRATIVE & COMPLEMENTARY MEDICINE ranking 16/30=53.3%) (MOST 112-2320-B-415-002). 本人為通訊作
2. C.H. Shen, P.Y. Li, S.C. Wang, S.R. Wu, C.Y. Hsieh, Y.C. Dai, **Yi-Wen Liu***. Epigenetic regulation of human WIF1 and DNA methylation situation of WIF1 and GSTM5 in urothelial carcinoma. **Heliyon 2023/05**, 9(5):e16004. (SCIE, IF 4.0, MULTIDISCIPLINARY SCIENCES ranking 23/73=31.5%) (MOST 108-2320-B-415-006-MY3). 本人為通訊作者
3. M.Y. Lin, L.G. Chen, Y.Y. Siao, T.H. Lin, I.A. Huang, **Yi-Wen Liu***, Chin-Chin Huang*. Composition and bioactivity analysis of a modified Huang-Lian-Jie-Du decoction. **Evidence-based Complementary and Alternative Medicine 2022/09**, 2022:2147923. (SCIE in 2021, IF 2.65, INTEGRATIVE & COMPLEMENTARY MEDICINE ranking 16/30=53.3%) (MOST 108-2320-B-415-006-MY3). 本人為共同通訊作者
4. C.H. Shen, J.Y. Wu, S.C. Wang, C.H. Wang, C.T. Hong, P.Y. Liu, S.R. Wu and **Yi-Wen Liu***. The suppressive role of phytochemical-induced glutathione S-transferase Mu 2 in human urothelial carcinoma cells. **Biomedicine & Pharmacotherapy 2022/07**, 151:113102. (SCIE, IF 7.5, PHARMACOLOGY & PHARMACY ranking 23/277=8.3%) (MOST 108-2320-B-415-006-MY3). 本人為通訊作者
5. Y.C. Dai, C.Y. Fang, H.Y. Yang, Y.J. Jian, S.C. Wang and **Yi-Wen Liu***. The correlation of epithelial-mesenchymal transition-related gene expression and the clinicopathologic features of colorectal cancer patients in Taiwan. **PLoS One 2021/07**, 16(7):e0254000. (SCIE, IF 3.7, MULTIDISCIEPLINARY SCIENCES ranking 26/73=35.6%) (MOST

108-2320-B-415-006-MY3). 本人為通訊作者

6. M.Y. Lee, M.Y. Lin, Y.J. Chang, Y.T. Tseng, I.A. Huang, W.T. Huang and **Yi-Wen Liu***. Efficacy and safety of modified Huang-Lian-Jie-Du decoction cream on cancer patients with skin side effects caused by EGFR inhibition. **Processes 2021/06**, 9(7):1081. (SCIE, IF 3.5, ENGINEERING, CHEMICAL ranking 63/140=45%) (MOST 108-2320-B-415-006-MY3). 本人為通訊作者
7. Y.C. Jou, S.C. Wang, Y.C. Dia, S.T. Wang, M.H. Yu, H.Y. Yang, L.C. Chen, C.H. Shen* and **Yi-Wen Liu***. Anti-cancer effects and tumor marker role of glutathione *S*-transferase Mu 5 in human bladder cancer. **International Journal of Molecular Sciences 2021/03,** 22(6):3056. (SCIE, IF 5.6, BIOCHEMISTRY & MOLECULAR BIOLOGY ranking 66/285=23.15%) (MOST 108-2320-B-415-006-MY3, MOST107-2320-B-415-001, MOST104-2320-B-415-001-MY3). 本人為通訊作者
8. Y.C. Jou, S.C. Wang, Y.C. Dai, S.Y. Chen, C.H. Shen, Y.R. Lee, L.C. Chen and **Yi-Wen Liu***. Gene expression and DNA methylation regulation of arsenic in the mouse bladders and in human urothelial cells. **Oncology Reports 2019/08**, 43(3):1005-1016. (SCIE, IF 4.2, ONCOLOGY ranking 94/241=39.0%) (MOST 107-2320-B-415-001). 本人為通訊作者
9. C.H. Shen, S.T. Wang, S.C. Wang, S.M. Lin, L.C. Lin, Y.C. Dai and **Yi-Wen Liu***. Ketamine-induced bladder dysfunction is associated with extracellular matrix accumulation and impairment of calcium signaling in a mouse model. **Molecular Medicine Reports 2019/04**, 19(4):2716-2728. (SCIE, IF 3.4, MEDICINE, RESEARCH & EXPERIMENTAL ranking 77/136=56.6%) (MOST 104-2320-B-415-001-MY3). 本人為通訊作者
10. Y.C. Dai, S.C. Wang, M.M. Haque, W.H. Lin, L.C. Lin, C.H. Chen and **Yi-Wen Liu***. The interaction of arsenic and *N*-butyl-*N*-(4-hydroxybutyl)nitrosamine on urothelial carcinogenesis in mice. **PLoS One 2017/10**, 12(10):e0186214. (SCIE, IF 3.7, MULTIDISCIEPLINARY SCIENCES ranking 26/73=35.6%) (MOST 104-2320-B-415-001-MY3). 本人為通訊作者
11. S.C. Wang, S.T. Wang, H.T. Liu, X.Y. Wang, S.C. Wu, L.C. Chen* and **Yi-Wen Liu***. Trichostatin A induces bladder cancer cell death via intrinsic apoptosis at the early phase and Sp1-survivin downregulation at the late phase of treatment. **Oncology Reports 2017/09**, 38:1587-1596. (SCIE, IF 4.2, ONCOLOGY ranking 94/241=39.0%) (MOST 104-2320-B-415-001-MY3). 本人為通訊作者
12. S.H. Wang, S.C. Wang, P.C. Chen, S.T. Wang, and **Yi-Wen Liu***. Induction of cyclooxygenase-2 gene by *Candida albicans* through EGFR, ERK and p38 pathways in human urinary epithelium. **Medical Mycology 2017/04**, 55:314-322. (SCIE, IF 2.9, VETERINARY SCIENCES ranking 14/143=9.79%) (MOST 104-2320-B-415-001-MY3). 本人為通訊作者

13. C.H. Shen, S.C. Wang, S.T. Wang, S.M. Lin, J.D. Wu, C.T. Lin, **Yi-Wen Liu***. Evaluation of urinary bladder fibrogenesis in mouse model of long-term ketamine injection. **Molecular Medicine Reports 2016/09**, 14:1880-1890. (SCIE, IF 3.4, MEDICINE, RESEARCH & EXPERIMENTAL ranking 77/136=56.6%) (NSC101-2320-B-415-002-MY3). 本人為通訊作者
14. M.Y. Lin, S.Y. Chiang, Y.Z. Li, M.F. Chen, Y.S. Chen, J.Y. Wu*, **Yi-Wen Liu***. Anti-tumor effect of Radix Paeoniae Rubra extract on mice bladder tumors using intravesical therapy. **Oncology Letters 2016/08**, 12:904-910. (SCIE, IF 2.9, ONCOLOGY ranking: 163/241=67.6%) (NSC101-2320-B-415-002-MY3). 本人為通訊作者
15. S.C. Wang, C.C. Huang, C.H. Shen, L.C. Lin, P.W. Zhao, S.Y. Chen, Y.C. Deng and **Yi-Wen Liu***. Gene expression and DNA methylation status of glutathione *S*-transferase Mu1 and Mu5 in urothelial carcinoma. **PLoS One 2016/07**, 11(7):e0159102. (SCIE, IF 3.7, MULTIDISCIEPLINARY SCIENCES ranking 26/73=35.6%) (MOST 104-2320-B-415-001-MY3). 本人為通訊作者
16. C.H. Shen, S.T. Wang, Y.R. Lee, S.Y. Liu, Y.Z. Li, J.D. Wu, Y.J. Chen, **Yi-Wen Liu***. Biological effect of ketamine in urothelial cell lines and global gene expression analysis in the bladders of ketamine-injected mice. **Molecular Medicine Reports 2015/02**, 11:887-895. (SCIE, IF 3.4, MEDICINE, RESEARCH & EXPERIMENTAL ranking 77/136=56.6%) (NSC101-2320-B-415-002-MY3). 本人為通訊作者
17. J.J. Chuang, Y.C. Dai, Y.L. Lin, Y.Y. Chen, W.H Lin, H.L. Chan, **Yi-Wen Liu***. Downregulation of glutathione *S*-transferase M1 protein in *N*-butyl-*N*-(4-hydroxybutyl)nitrosamine-induced mouse bladder carcinogenesis. **Toxicology and Applied Pharmacology 2014/09**, 279:322-330. (SCIE, IF 3.8, TOXICOLOGY ranking: 29/94=30.8%) (NSC101-2320-B-415-002-MY3). 本人為通訊作者
18. M.Y. Lin, Y.R. Lee, S.Y. Chiang, Y.Z. Li, Y.S. Chen, C.D. Hsu, **Yi-Wen Liu***. Cortex Moutan induces bladder cancer cell death via apoptosis and retards tumor growth in mouse bladders. **Evidence-Based Complementary and Alternative Medicine 2013/10**, 2013: Article ID 207279. (SCIE in 2021, IF 2.650, INTEGRATIVE & COMPLEMENTARY MEDICINE ranking: 16/30=53.3%) (NSC101-2320-B-415-002-MY3). 本人為通訊作者
19. J.Y. Wu, K.W. Tsai, Y.Z. Li, Y.S. Chang, Y.C. Lai, Y.H. Laio, J.D. Wu, **Yi-Wen Liu***. Anti-bladder tumor effect of baicalein from *Scutellaria baicaleinsis* Georgi and its application in vivo. **Evidence-Based Complementary and Alternative Medicine 2013/05**, 2013: Article ID 579751. (SCIE in 2021, IF 2.650 in 2021, INTEGRATIVE & COMPLEMENTARY MEDICINE ranking: 16/30=53.3%) (NSC101-2320-B-415-002-MY3). 本人為通訊作者
20. M.H. Chen, M.Y. Lee, J.J. Chuang, Y.Z. Li, S.T. Ning, J.C. Chen, **Yi-Wen Liu***. Curcumin inhibits HCV replication by heme oxygenase-1 induction and AKT inhibition. **International Journal of Molecular Medicine 2012/11**, 30:1021-1028. (SCIE, IF 5.

4, MEDICINE, RESEARCH & EXPERIMENTAL ranking: 39/189=20.6%) (NSC98-2320-B-415-002-MY3). 本人為通訊作者

21. S.Y. Wu, Y.R. Lee, C.C. Huang, Y.Z. Li, Y.S. Chang, C.Y. Yang, J.D. Wu, **Yi-Wen Liu***. Curcumin-induced heme oxygenase-1 expression plays a negative role for its anti-cancer effect in bladder cancers. **Food and Chemical Toxicology 2012/10**, 50:3530-3536. (SCIE, IF 4.3, TOXICOLOGY ranking: 20/94=21.27%) (NSC98-2320-B-415-002-MY3). 本人為通訊作者
22. P.Y. Lin, Y.L. Lin, C.C. Huang, S.S. Chen, **Yi-Wen Liu***. Inorganic arsenic in drinking water accelerates *N*-butyl-*N*-(4-hydroxybutyl)nitrosamine-induced bladder tissue damage in mice. **Toxicology and Applied Pharmacology 2012/02**, 259(1):27-37. (SCIE, IF 3.8, TOXICOLOGY ranking: 29/94=30.8%) (NSC98-2320-B-415-002-MY3). 本人為通訊作者
23. **Yi-Wen Liu**, S.A. Wang, T.Y. Hsu, T. A. Chen, W.C. Chang*, J.J. Hung*. Inhibition of LPS-induced C/EBPδ by trichostatin A has a positive effect on LPS-induced cyclooxygenase 2 expression in RAW264.7 cells. **Journal of Cellular Biochemistry 2010/08**, 110(6):1430-1438. (SCIE, IF 4.0, BIOCHEMISTRY & MOLECULAR BIOLOGY ranking: 119/285=41.75%). 本人為第一作者
24. C.H. Shen, J.J. Shee, J.Y. Wu, Y.W. Lin, J.D. Wu, **Yi-Wen Liu***. Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumor growth in a murine orthotopic bladder tumor model. **British Journal of Pharmacology 2010/08**, 160(8):2008-2027. (SCIE, IF 7.3, PHARMACOLOGY & PHARMACY ranking: 25/277=9.0%) (NSC98-2320-B-415-002-MY3). 本人為通訊作者
25. J.Y. Wu, K.W. Tsai, J.J. Shee, Y.J. Li, C.H. Chen, J.J. Chuang, **Yi-Wen Liu***. 4'-Chloro-3,5-dihydroxystilbene, a resveratrol derivative, induces lung cancer cell death. **Acta Pharmacologica Sinica 2010/01**, 31:81-92. (SCIE, IF 8.2, PHARMACOLOGY & PHARMACY ranking: 17/277=6.1%) (NSC97-2320-B-415-002). 本人為通訊作者
26. M.H. Chen, Q.F. Wang, L.G. Chen, J.J. Shee, J.C. Chen, K.Y. Chen, S.H. Chen, J.G.J. Su, **Yi-Wen Liu***. The inhibitory effect of *Gynostemma pentaphyllum* on MCP-1 and type I procollagen expression in rat hepatic stellate cells. **Journal of Ethnopharmacology 2009/10**, 126:42-49. (SCIE, IF 5.4, INTEGRATIVE & COMPLEMENTARY MEDICINE ranking: 4/28=14.28%) (NSC97-2320-B-415-002). 本人為通訊作者
27. L.G. Chen, L.Y. Hung, K.W. Tsai, Y.S. Pan, Y.D. Tsai, Y.Z. Li, **Yi-Wen Liu***. Wogonin, a bioactive flavonoid in herbal tea, inhibits inflammatory cyclooxygenase-2 gene expression in human lung epithelial cancer cells. **Molecular Nutrition & Food Research 2008/11**, 52:1349-1357. (SCIE, IF 5.2, FOOD SCIENCE & TECHNOLOGY ranking: 34/142=23.9%) (NSC-95-2320-B-415-004). 本人為通訊作者
28. M.H. Chen, S.H. Chen, Q.F. Wang, J.C. Chen, D.C. Chang, S.L. Hsu, C.H. Chen, C.R. Sheue, **Yi-Wen Liu***. The molecular mechanism of gypenosides-induced G1 growth

arrest of rat hepatic stellate cells. **Journal of Ethnopharmacology 2008/05**, 117:309-317. (SCIE, IF 5.4, INTEGRATIVE & COMPLEMENTARY MEDICINE ranking: 4/28=14.28%) (NSC95-2320-B-415-004). 本人為通訊作者

[2008 年至今，非 first author, 非 corresponding author]

29. C.H. Wong, W.L. Chang, F.J. Lu, Yi-Wen Liu, J.Y. Peng and C.H. Chen*. Parecoxib expresses anti-metastasis effect through inhibition of epithelial-mesenchymal transition and the Wnt/beta-catenin signaling pathway in human colon cancer DLD-1 line. **Environmental Toxicology 2022/11**, 37(11)2718-2727.
30. C.F. Wu, C.Y. Wu, C.F. Lin, Y.W. Liu, T.C. Lin, H.J. Liao and G.R. Chang*. The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice. **Biomedicine & Pharmacotherapy 2022/07**, 151(2022)113128. (SCIE)
31. H.J. Lin, J.H. Ho, L.C. Tsai, F.Y. Yang, L.L. Yang, C.D. Kuo, L.G. Chen, **Yi-Wen Liu** and Jin-Yi Wu*. Synthesis and in vitro photocytotoxicity of 9-/13-lipophilic substituted berberine derivatives as potential anticancer agents. **Molecules 2020/02**, 25:677. (SCIE)
32. C.H. Lu, S.H. Chen, Y.S. Chang, **Y.W. Liu**, J.Y. Wu, Y.P. Lim, H.I. Yu, Y.R. Lee*. Honokiol, a potential therapeutic agent, induces cell cycle arrest and program cell death in vitro and in vivo in human thyroid cancer cells. **Pharmacological Research 2017/01**, 115:288-298. (SCIE)
33. S.T. Yang, C.J. Yen, C.H. Lai, Y.J. Lin, K.C. Chang, J.C. Lee, Y.W. Liu, P.Y. Chang-Liao, L.S. Hsu, W.C. Chang, W.C. Hung, T. K. Tang, **Y.W. Liu**, L.Y. Hung *. SUMOylated CPAP is required for IKK-mediated NF-κB activation and enhances HBx-induced NF-κB signaling in HCC. **Journal of Hepatology 2013/06**, 58:1157-1164. (SCIE)
34. M.Y. Lee, **Y.W. Liu**, M.H. Chen, J.Y. Wu, H.Y. Ho, Q.F. Wang, J.J. Chuang*. Indirubin-3'-monoxime promotes autophagic and apoptotic death in JM1 human acute lymphoblastic leukemia cells and K562 human chronic myelogenous leukemia cells. **Oncology Reports 2013/05**, 29:2072-2078. (SCIE)
35. C.C. Fang, F.Y. Chen, C.R. Chen, C.C. Liu, L.C. Wong, **Y.W. Liu**, J.G. Su*. Cyprodinil as an activator of aryl hydrocarbon receptor. **Toxicology 2013/02**, 304:32-40. (SCIE)
36. C.H. Lu, **Y.W. Liu**, S.C. Hua, H.I. Yu, Y.P. Chang and Y.R. Lee*. Autophagy induction in reversine treated human follicular thyroid cancer cells. **Biomedicine & Pharmacotherapy 2012/12**, 66:642-647. (SCIE)
37. S.C. Hua, T.C. Chang, H.R. Chen, C.H. Lu, **Y.W. Liu**, S.H. Chen, H.I. Yu, Y.P. Chang, Y.R. Lee*. Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells. **Pharmaceutical Research 2012/07**, 29:1990-2005. (SCIE)
38. J.Y. Wu, C.H. Chen, W.H Chang., K.T. Chung, **Y.W. Liu**, F.J. Lu, C.H. Chen*. Anti-

Cancer Effects of Protein Extracts from Calvatia lilacina, Pleurotus ostreatus and Volvariella volvacea. **Evidence-Based Complementary and Alternative Medicine 2011/06**, Article ID 982368. (SCIE)

39. C.H. Lai, J.T. Tseng, Y.C. Lee, Y.J. Chen, J.C. Lee, B.W. Lin, T.C. Hung, Y.W. Liu, T.H. Leu, **Y.W. Liu**, Y.P. Chen, W.C. Chang, L.Y. Hung*. Translational up-regulation of Aurora-A in EGFR-overexpressed cancer. Journal of Cellular and Molecular Medicine **2010/06**, 14(6B):1520-1531. (SCIE)
40. M.T. Chou, W.C. Chu, W.F. Hong, M.C. Huang, W.J. Liu, S.C. Lin, S.C. Huang, F.Y. Chen, W.F. Hsiao, **Y.W. Liu**, J.Y. Wu, J.G.J. Su*. 1,10-Phenanthroline stabilizes mRNA of the carcinogen-metabolizing enzyme, cytochrome P450 1a1. **Toxicology Letters 2010/02**, 192(2):252-260. (SCIE)
41. Y.J. Chen, W.M. Chang, **Y.W. Liu**, C.Y. Lee, Y.H. Jang, C.D. Kuo*, H.F. Liao*. A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells. **Chemico-Biological Interactions 2009/10**, 181: 440-446. (SCIE)
42. S.H. Wang, C.T. Liang, **Y.W. Liu**, M.C. Huang, S.C. Huang, W.F. Hong, J.G.J. Su*. Crosstalk between activated forms of the aryl hydrocarbon receptor and glucocorticoid receptor. **Toxicology 2009/08**, 262: 87-97. (SCIE)
43. S.A. Wang, J.Y. Chuang, S.H. Yeh, Y.T. Wang, **Y.W. Liu**, W.C. Chang*, J.J. Hung*. Heat shock protein 90 is important for Sp1 stability during mitosis. **Journal of Molecular Biology 2009/04**, 387:1106-1119. (SCIE)
44. J.Y. Wu, K.T. Chung, **Y.W. Liu**, F.J. Lu, R.S. Tsai, C.H. Chen, C.H. Chen*. Synthesis and biological evaluation of novel C(6) modified baicalein derivatives as antioxidative agents. **Journal of Agricultural and Food Chemistry 2008/04**, 56:2838-2845. (SCIE)
45. J.Y. Chuang, Y.T. Wang, S.H. Yeh, **Y.W. Liu**, W.C. Chang*, J.J. Hung*. Phosphorylation by c-Jun NH2-terminal kinase 1 regulates the stability of transcription factor Sp1 during mitosis. **Molecular Biology of the Cell 2008/03**, 19:1139-1151. (SCIE)

[2007 年以前]

46. **Yi-Wen Liu*,** C.C. Chen, J.M. Wang, W.C. Chang, Y. C. Huang, S.Y. Chung, B.K. Chen, J.J. Hung. Role of transcriptional factors Sp1, c-Rel and c-Jun in LPS-induced C/EBPδ gene expression of mouse macrophages. **Cellular and Molecular Life Sciences 2007/12**, 64:3282-3294. (SCI) (NSC-93-2320-B-415-002). 本人為第一作者
47. C.C.Chen, **Y.W. Liu**, Y.B. Ker, Y.Y. Wu, E.Y. Lai, C.C.Chyau*, T.H. Hseu, R.Y. Peng. Chemical characterization and anti-inflammatory effect of polysaccharide fractionated from submerge-cultured *Antrodia camphorata* mycelia. **Journal of Agricultural and Food Chemistry 2007/06**, 55:5007-5012. (SCI).
48. M.H. Chen*, Q.F. Wang, S.L. Hsu, L.I. Hsu, H.Y. Hsieh, W.C. Wang, **Y.W. Liu**, S.H. Chen, J.C. Chen. The anti-proliferation effect of gypenosides in culture rat hepatic

stellate cell. **Journal of Integrated Chinese and Western Medicine 2007/06**, 9: 1-10.

49. Y.C. Huang, W.C. Chang, J.G.J. Su, J.L. Cia, C.C. Chen, J.J. Hung, **Yi-Wen Liu***. Peptidoglycan enhances transcriptional expression of CCAAT/enhancer-binding protein δ gene in mouse macrophages. **Journal of Biomedical Science 2007/05**, 14: 407-418. (SCI) (NSC-93-2320-B-415-002; 94-2815-C-415-007-B). 本人為通訊作者
50. B. Djoko, R.Y.-Y. Chiou, J.J. Shee, **Yi-Wen Liu***. Characterization of immunological activities of peanut stilbenoids, arachidin-1, piceatannol and resveratrol on lipopolysaccharide-induced inflammation of RAW 264.7 macrophages. **Journal of Agricultural and Food Chemistry 2007/03**, 55:2376-2383. (SCI). (NSC-93-2320-B-415-002). 本人為通訊作者
51. Y.Y. Wu, C.C.Chen, C.C.Chyau, S.Y. Chung, **Yi-Wen Liu***. Modulation of inflammation-related genes of polysaccharides fractionated from mycelia of medicinal basidiomycete *Antrodia camphorata*. **Acta Pharmacologica Sinica 2007/02**, 28:258-267. (SCI) (NSC-93-2320-B-415-002). 本人為通訊作者
52. S.H. Kuo, T.Z. Liu, **Y.W. Liu**, W.C. Tsenge, R.H. Liu, F.J. Lu, Y.S. Lin, C.Y. Chen and C.H. Chen*. 6-shogaol (alkanone from Ginger) induces apoptotic cell Death of human hepatoma p53 mutant mahlavu subline via an oxidative stress-mediated caspase-dependent mechanism. **Journal of Agricultural and Food Chemistry 2007/02**, 55:948-954. (SCI).
53. C.Y. Chen*, C.H. Chen, C.H. Wong, **Y.W. Liu**, Y.S. Lin, Y.D. Wang and Y.R. Hsui. Cytotoxic constituents of the stems of *Cinnamomum subavenium*. **Journal of Natural Products 2007/01**, 70:103-106. (SCI).
54. J.C. Chang, Y.H. Lai, B. Djoko, P.L. Wu, C.D. Liu, **Y.W. Liu**, R.Y.-Y. Chiou*. Biosynthesis enhancement and antioxidant and anti-inflammatory activities of peanut (*Arachis hypogaea* L.) arachidin-1, arachidin-3 and isopentadienylresveratrol. **Journal of Agricultural and Food Chemistry 2006/12**, 54:10281-10287. (SCI).
55. B.T. Chiang, **Y.W. Liu,** B.K. Chen, J.M. Wang, W.C. Chang*. Direct interaction of C/EBPδ and Sp1 at the GC-enriched promoter region synergizes the IL-10 gene transcription in mouse macrophage. **Journal of Biomedical Science 2006/09**, 13:621-635. (SCI).
56. **Yi-Wen Liu**, C.C. Chen, H.P. Tseng, W.C. Chang*. Lipopolysaccharide-induced transcriptional activation of interleukin-10 is mediated by MAPK- and NF-κB-induced CCAAT/enhancer-binding protein δ in mouse macrophages. **Cellular Signalling 2006/09**, 18:1492-1500. (SCI) (NSC-91-2320-B-415-003). 本人為第一作者
57. **Yi-Wen Liu**, H.P. Tseng, L.C. Chen, B.K. Chen, W.C. Chang*. Functional cooperation of Sp1 and C/EBP β and δ in lipopolysaccharide-induced gene activation of interleukin-10 in mouse macrophages. **The Journal of Immunology 2003/07**, 171:821-828. (SCI) (NSC-89-B-041-2320-017) (NSC-90-B-041-2320-017). 本人為第一作者
58. L.C. Chen, B.K. Chen, **Y.W. Liu**, W.C. Chang*. Induction of 12-lipoxygenase

expression by transforming growth factor-alpha in human epidermoid carcinoma A431 cells. **FEBS Letters 1999**, 455(1-2):105-110. (SCI).

59. Y.W. Liaw, **Y.W. Liu**, B.K. Chen, W.C. Chang*. Induction of 12-lipoxygenase expression by phorbol 12-myristate 13-acetate in human epidermoid carcinoma A431 cells. **Biochimica et Biophysica Acta-Lipids and Lipid Metabolism 1998**, 1389(1):23-33. (SCI).
60. W.C. Chang*, **Y.W. Liu**, Y. Asaoka, H. Suzuki, T. Yoshimoto, S. Yamamoto. Induction of 12-lipoxygenase expression by epidermal growth factor is mediated by protein kinase C in A431 cells. **Adv. Exp. Med. Biol. 1997**, 400A: 525-529.
61. W.C. Chang*, **Y.W. Liu**, B.K. Chen, C.J. Chen. Regulation of 12-lipoxygenase expression by epidermal growth factor in human epidermoid carcinoma A431 cells. **Adv. Exp. Med. Biol. 1997**, 407:33-40.
62. **Yi-Wen Liu**, T. Arakawa, S. Yamamoto, W.C. Chang*. Transcriptional activation of human 12-lipoxygenase gene promoter is mediated through Sp1 consensus sites in A431 cells. **Biochemical Journal 1997**, 324 (Pt 1):133-140. (SCI). 本人為第一作者
63. **Yi-Wen Liu**, B.K. Chen, C.J. Chen, T. Arakawa, T. Yoshimoto, S. Yamamoto, W.C. Chang*. Epidermal growth factor enhances transcription of human arachidonate 12-lipoxygenase in A431 cells. **Biochimica et Biophysica Acta-Lipids and Lipid Metabolism 1997**, 1344(1):38-46. (SCI). 本人為第一作者
64. B.K. Chen, **Y.W. Liu**, S. Yamamoto, W.C. Chang*. Overexpression of Ha-ras enhances the transcription of human arachidonate 12-lipoxygenase promoter in A431 cells. **Biochimica et Biophysica Acta-Lipids and Lipid Metabolism 1997**, 1344(3):270-277. (SCI).
65. W.C. Chang*, H.C. Kao, **Y.W. Liu**. Down-regulation of epidermal growth factor-induced 12-lipoxygenase expression by glucocorticoids in human epidermoid carcinoma A431 cells. **Biochemical Pharmacology 1995**, 50(7):947-952. (SCI).
66. **Yi-Wen Liu**, Y. Asaoka, H. Suzuki, T. Yoshimoto, S. Yamamoto, W.C. Chang*. Induction of 12-lipoxygenase expression by epidermal growth factor is mediated by protein kinase C in A431 cells. **Journal of Pharmacology and Experimental Therapeutics 1994**, 271(1):567-573. (SCI). 本人為第一作者
67. W.C. Chang*, **Y.W. Liu**, C.C. Ning, H. Suzuki, T. Yoshimoto, S. Yamamoto. Induction of arachidonate 12-lipoxygenase mRNA by epidermal growth factor in A431 cells. **Journal of Biological Chemistry 1993**, 268(25):18734-18739. (SCI).

Conference presentations (only after 2008)

研討會論文發表 (只列 2008 年後之通訊作者發表)

1. Shou-Chieh Wang (王守玠), **Yi-Wen Liu**, Jin-Yi Wu, Hsin-Ting Liu. (2023/12). The

anticancer effect of two-drug combination regimens in bladder cancer cell lines. 2023 Annual Meeting of Taiwan Society of Nephrology, Taipei, Taiwan.

2. 鄧姝齊、何尚哲、**劉怡文**。(2023/10). 紅檜及臺灣扁柏甲醇抽出成分抑制膀胱癌 BFTC 905 細胞株生長活性之初探。112 年森林資源永續發展研討會，宜蘭，台灣。**本論文獲選學生壁報展演第二名**。
3. **Yi-Wen Liu** (2022/04). 膀胱癌的小鼠治療模式與基因檢測研究。台灣泌尿科醫學會半年會，嘉義，台灣。(邀請演講)
4. Kah-Min Lee (李嘉雯) and **Yi-Wen Liu***. (2022/03). Vorinostat and Doxorubicin improved Anticancer Effect in Bladder Cancer Cells. The 36th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
5. Pei-Yu Li (李姵諭) and **Yi-Wen Liu***. (2021/11). Epigenetic regulation and anti-bladder cancer effect of *WIF1* gene by decitabine and trichostatin A. 第三屆台灣藥學學術聯合研討會。**本論文獲選進入口頭論文比賽**。
6. Chen-Tai Hong (洪晨泰), Pei-Yu Liu (劉佩俞), Chih-Yu Hsieh, Jin-Yi Wu* and **Yi-Wen Liu***. (2021/11). Berberrubine-induced glutathione *S*-transferase Mu 2 inhibits migration and invasion of human urothelial carcinoma cells. 14th Asia Pacific Federation of Pharmacologists, Taipei, Taiwan.
7. Shou-Chieh Wang (王守玠), Yeong-Chin Jou, Cheng-Huang Shen and **Yi-Wen Liu***. (2020/10). The Potential Role of glutathione *S*-transferase Mu 5 in Bladder Cancer Cells. 2020 International Conference on Biotechnology and Healthcare, Chiayi, Taiwan.
8. Tzu-Ying Yang (楊子瑩), Yeong-Chin Jou, Cheng-Huang Shen and **Yi-Wen Liu***. (2020/10). The Potential RNA Expression Regulation of Nicotine-Promoted Metastasis in T24 Bladder Cancer Cells. 2020 International Conference on Biotechnology and Healthcare, Chiayi, Taiwan. **本論文獲其他生技相關組壁報論文獎第一名**
9. Kah-Min Lee (李嘉雯) and **Yi-Wen Liu***. (2020/10). Co-treatment of vorinostat with doxorubicin synergistically enhances anticancer effect in bladder cancer cells. 2020 International Conference on Biotechnology and Healthcare, Chiayi, Taiwan. **本論文獲醫療與健康照護組壁報論文獎第二名**
10. **Yi-Wen Liu***. (2020/09). Phytochemical searching targeting for induction of glutathione *S*-transferase Mu gene. The 35th Symposium of Natural Products, Taipei, Taiwan. (邀請演講)
11. Hsin-Jou Lee (李欣柔), Pei-Yu Li (李姵諭), Yih-Yuan Chen and **Yi-Wen Liu***. (2020/02). Gene Expression of WNT Inhibitory Factor 1 Regulated by DNA Methylation and Histone Acetylation in Bladder Cancer Cells. 27th Symposium on Recent Advances in Cellular and Molecular Biology, Kenting, Taiwan.
12. Nien-Chi Li (李念綺), Lei-Chin Chen and **Yi-Wen Liu***. (2020/02). Mechanism study of chemicals inducing expression of human glutathione *S*-transferase Mu gene family.

27th Symposium on Recent Advances in Cellular and Molecular Biology, Kenting, Taiwan.

13. Kah-Min Lee (李嘉雯)#, Chi-Hung Wang (王琦泓)#, Nien-Chi Li, Shou-Tsung Wang, **Yi-Wen Liu***. (2019/10). Phytochemicals Activate the Gene Expression of Human GSTM2 and GSTM3 in Bladder Cancer Cells. The 34th Symposium of Natural Products, Taoyuan, Taiwan.
14. Shou-Tsung Wang (王守琮), Cheng-Huang Shen, Yuan-Chang Dai, Chin-Chin Huang, **Yi-Wen Liu***. (2019/03). Extracellular Matrix Accumulation and Impairment of Calcium Signaling Are Involved in Ketamine-induced Bladder Dysfunction in A Mouse Model. The 34th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
15. Chi-Hung Wang (王琦泓), Lei-Chin Chen , **Yi-Wen Liu***. (2019/03). Analysis of transcription Factors Regulating the Gene Expression of Human *GSTM2*、*M3* in Bladder Cancer Cells. The 34th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
16. Chi-Hung Wang (王琦泓), Yu-Chiao Deng, Ting-Jia, Jhang, Yu-Chun Yen, Chen-Wei Lai and **Yi-Wen Liu***. (2018/06). Functional role and gene promoter regulation of glutathione *S*-transferase Mu 1~5 in human bladder cancer. The 15th Symposium of the Frontiers of Biomedical Sciences, Taichung, Taiwan。第 15 屆前瞻生物醫學科學新知研討會。
17. Shih-Ying Chen (陳詩穎), Yuan-Chang Dai, Min-Hua Yu, Shin-Hua Shie and **Yi-Wen Liu***. (2018/06). DNA Methylation Level of *GSTM5* and *Wif1* as the Novel Biomarkers for Human Bladder Cancer. The 15th Symposium of the Frontiers of Biomedical Sciences, Taichung, Taiwan。第 15 屆前瞻生物醫學科學新知研討會。
18. Chun-Tzu Lai (賴純資), Pei-Min Ding, Shou-Chieh Wang, Shou-Tsung Wang and **Yi-Wen Liu***. (2018/06). Evaluation of combination effect of current intravesical medicine and non-intravesical marketed drugs in mice orthotopic bladder tumor model. The 15th Symposium of the Frontiers of Biomedical Sciences, Taichung, Taiwan。第 15 屆前瞻生物醫學科學新知研討會。
19. Shih-Ying Chen (陳詩穎), Pei-Wen Zhao, Yu-Chiao Deng, Min-Hua Yu and **Yi-Wen Liu***. (2018/01). Compensation of glutathione *S*-transferase (GST) Mu1-null by a high identical GST superfamily member GSTM5 through DNA demethylation. 第一屆台灣藥學學術聯合研討會。**本論文獲得壁報論文比賽優等獎**。
20. Shih-Ying Chen (陳詩穎), Pei-Wen Zhao and **Yi-Wen Liu***. (2017/03). Effect of inorganic arsenic on the histological and gene expression change of bladder urothelium. The 32th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
21. Yu-Chiao Deng (鄧羽喬) and **Yi-Wen Liu***. (2017/03). Effects of Glutathione *S*-transferase Mu 2, 3 and 5 on the Malignant Phenotype in Human Bladder Cancer Cells. The 32th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
22. Pei-Ching Chen (陳佩青), Shao-Hung Wang and **Yi-Wen Liu***. (2015/03). Analysis

of Proinflammatory Response in Human Urinary Epithelial Cells Infected by *Candida albicans*. The 30th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.

23. Pei-Wen Zhao (趙珮雯) and **Yi-Wen Liu*** (2015/03). Study of DNA Methylation Affecting Glutathione *S*-Transferase Mu 1 Gene Expression in Bladder cancer. The 30th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
24. Pei-Ching Chen (陳佩青), Ya-Hsien Tseng (曾雅嫻), Shao-Hung Wang, and **Yi-Wen Liu***. (2014/09). Analysis of Proinflammatory Response in Human Urinary Epithelial Cells Infected by *Candida albicans*. Taiwan Yeast Meeting 2014, Taipei, Taiwan.
25. Mei-Yi Lin (林美儀), Su-Yin Chiang and **Yi-Wen Liu*** (2013/05). Cortex Moutan induces bladder cancer cell death via apoptosis and retards tumor growth in mouse bladders. International Conference of Traditional and Complementary Medicine on Health 2013, Taipei, Taiwan.
26. Shiau-Yuan Liu (劉筱媛), Jyan-Gwo J. Su and **Y.W. Liu*** (2012/03). Ketamine abuse-related bladder damage. The 27th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
27. Zhang-Jin Zheng (鄭長晉), Jyan-Gwo J. Su and **Y.W. Liu*** (2012/03). Mechanism of honokiol-potentiated cytoxicity in baicalein-treated bladder cancer cells BFTC 905. The 27th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
28. Yung-Lun Lin (林永倫) and **Yi-Wen Liu*** (2012/02). Inorganic arsenic in drinking water accelerates N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder tissue damage in Mice. 20th Symposium on Recent Advances in Cellular and Molecular Biology, Kaohsiung, Taiwan.
29. C.Y. Yang (楊筑譯), J.J. Shee, **Y.W. Liu*** (2010/06). The anti-invasive effect of curcumin in human bladder cancer cells: the role of heme oxygenase-1. BIT's 3rd Annual World Cancer Congress-2010, **Singapore EXPO, Singapore.**
30. Y.H. Liao (廖禹涵), J.J. Shee, **Y.W. Liu*** (2010/06). Comparative effect of two antioxidants, curcumin and baicalein, on experimental pulmonary metastasis of bladder cancer cells. BIT's 3rd Annual World Cancer Congress-2010, **Singapore EXPO, Singapore.**
31. Y.H. Liao (廖禹涵) and **Y.W. Liu*** (2010/03). The effect of curcumin on the expression of superoxide dismutase in human bladder cancer cells. The 25th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
32. C.Y. Yang (楊筑譯) and **Y.W. Liu*** (2010/03). The effect of curcumin on inhibiting human bladder cancer cell invasion. The 25th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
33. Y.W. Lin (林怡玟), J.J. Shee, C.H. Shen, **Y.W. Liu*** (2009/03). Effect of Anti-Cancer Drug Combretastatin A-4 in Human Bladder Cancer Cells. The 24th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
34. Y.Z. Li (李宜蓁), J.Y. Wu, K.W. Tsai, **Y.W. Liu*** (2009/03). Mechanism Study of

Resveratrol Analogue 4'-Chloro-3,5-dihydroxystilbene-induced Cell Death in Human Lung Carcinoma Cells. The 24th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.

35. K.Y. Chen (陳克宇), M.H. Chen, Q.F. Wang, **Y.W. Liu*** (2009/03). The Molecular Mechanism of *Gynostemma pentaphyllum*-reduced Type1 Procollagen Expression in Rat Hepatic Stellate Cells. The 24th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.
36. **Yi-Wen Liu***, Jia-Jen Shee, Ke-Yu Chen, Ming-Ho Chen and Qwa-Fun Wang. (2009/02). The Molecular Mechanism of *Gynostemma pentaphyllum*-reduced Type1 Procollagen Expression in Rat Hepatic Stellate Cells. The 19th Conference of the APASL, **Hong Kong, China.**
37. S.Y. Chung (鍾欣怡), K.Y. Chen, **Y.W. Liu*** (2008/03). Identification of the different signal pathway between TLR4- and TLR2-induced C/EBPδ gene expression in mouse macrophages. The 23th Joint Annual Conference of Biomedical Science, Taipei, Taiwan.

Thesis (學位論文)：

1. **Yi-Wen Liu** (1997/03) Regulation of arachidonate 12-lipoxygenase gene expression by epidermal growth factor. Ph.D. Thesis, adviser: Academician Wen-Chang Chang (博士論文，指導教授：張文昌院士)。
2. **Yi-Wen Liu** (1993/06) Regulation of 12-lipoxygenase expression induced by epidermal growth factor in A431 cells. M.S. Thesis, adviser: Academician Wen-Chang Chang (碩士論文，指導教授：張文昌院士)。

Ph.D. Yi-Wen Liu (middle) graduated from National Cheng Kung University in 1997 (left: Dean Nai-Shan Wang, right: Academician Wen-Chang Chang)
1997 年劉怡文博士(中)在成大畢業典禮合照

（左：王乃三院長，右：張文昌院士）